BioCanada
Filter News
Found 36,220 articles
-
InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications
3/28/2024
IPA, InterSystems, a creative data technology provider dedicated to helping customers solve their most critical scalability, interoperability, and speed challenges, together with ImmunoPrecise Antibodies Ltd., an artificial intelligence-driven biotherapeutic research and technology company, are thrilled to announce a landmark collaboration.
-
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
3/28/2024
Aeterna Zentaris Inc. and Ceapro Inc. are pleased to announce that the Court of King's Bench of Alberta has issued a final order approving the arrangement described in the previously announced definitive agreement to combine the operations of Ceapro and Aeterna in an all-stock merger of equals transaction.
-
Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia
3/28/2024
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced the resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for etripamil, the Company’s lead investigational product for the management of paroxysmal supraventricular tachycardia (PSVT).
-
Canadian MedTech Startup Amplifies Fight Against Tuberculosis with New Grant
3/28/2024
Canadian-based Noze, a global leader in the breath-based diagnostic space, announced it received a new grant from the Bill & Melinda Gates Foundation, bringing the foundation's total grant funding to Noze to $1.8 million.
-
RefleXion and Limbus AI Announce Technology Integration to Expedite Cancer Treatment Planning
3/28/2024
RefleXion Medical, Inc. and Limbus AI, Inc. announced a licensing agreement to incorporate Limbus’ automated contouring software, Limbus Contour, into the RefleXion® X1 radiotherapy treatment planning system.
-
Sirona Biochem Announces 2023 Annual Meeting Results
3/28/2024
Sirona Biochem Corp. announces the voting results from its Annual General Meeting of Shareholders, held in Vancouver, British Columbia on March 28, 2024.
-
Spectral Medical Announces Fourth Quarter and Fiscal 2023 Results and Provides Corporate Update97 patients enrolled
3/28/2024
Spectral Medical Inc., a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, announced its financial results for the fourth quarter and for the year ended December 31, 2023 and provided a corporate update.
-
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
3/28/2024
Zymeworks Inc. announced the appointment of Dr. Neil Gallagher to its board of directors effective April 2, 2024.
-
Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform
3/28/2024
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced two posters will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2024.
-
Perimeter Medical Imaging AI Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
3/28/2024
Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) ("Perimeter" or the "Company") – a commercial-stage medical technology company – today reported financial results for the quarter and year ended December 31, 2023 and provided a corporate update.
-
Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark OfficeNovel Composition of MDMA Enantiomers leading to next-generation MDMA possibilities
3/27/2024
PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF) is extremely pleased to announce that the US Patent and Trademark Office (USPTO) has indicated it is issuing an allowance for the granting of a patent for ALA-002, the company’s lead investigational MDXX Novel Chemical Entity (NCE).
-
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
3/27/2024
Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R) announced today that it has submitted a Type C meeting request package to the U.S. Food & Drug Administration (“FDA”) for the evaluation of a proposed clinical study of Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long-term COVID.
-
Synaptive Medical Receives FDA 510(k) Clearance for Near-Infrared Fluorescence Visualization, Expanding Application of Existing Robotic Exoscope
3/27/2024
Synaptive Medical Inc. has received 510(k) clearance from the Food and Drug Administration (FDA) for its Near-Infrared fluorescence visualization module, Modus IR, adding to the existing fluorescence offering on its 4K 3D robotic exoscope, Modus X.
-
Theralase(R) Release's 4Q2023 Interim Financial Statements
3/27/2024
Theralase® Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds for the safe and effective destruction of various cancers, bacteria and viruses has released the Company's audited annual consolidated 2023 financial statements.
-
Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
3/27/2024
Aeterna Zentaris Inc. reported its financial and operating results for the year ended December 31, 2023 and provided an update on the completion of enrollment for its ongoing Phase 3 safety and efficacy study AEZS-130-P02 evaluating macimorelin for the diagnosis of Childhood Onset Growth Hormone Deficiency.
-
XORTX Announces New Clinical Advisory Board Member - March 27, 2024
3/27/2024
XORTX Therapeutics Inc., a biopharmaceutical company focused on developing innovative therapies to treat autosomal dominant polycystic kidney disease, is pleased to announce that Dr. Ronald Perrone has joined the Company’s Clinical Advisory Board.
-
Zymeworks Announces Participation in Upcoming April 2024 Investor Conferences
3/27/2024
Zymeworks Inc., a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, announced that management will participate in the following upcoming investor conferences.
-
Congruence Therapeutics to Present at Multiple Upcoming Investor Conferences - March 27, 2024
3/27/2024
Congruence Therapeutics, a computationally-driven biotechnology company building a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function, announced that it will participate in the following investor conferences.
-
BioSyent Announces Grant of Restricted Share Units - March 27, 2024
3/27/2024
BioSyent Inc. announces that its Board of Directors has approved a grant of 66,020 Restricted Share Units “RSUs” to certain directors, officers, management, and employees of the Company pursuant to the Company’s Restricted Share Unit Plan.
-
Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise
3/27/2024
NurExone Biologic Inc., is pleased to announce that, the Company completed a combined exercise and expiration of 12,682,340 common share purchase warrants issued pursuant to a private placement of units that closed on June 15, 2022.